Andrew J Plodkowski

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4202025/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. Journal of Clinical Oncology, 2018, 36, 633-641.	1.6	1,109
2	<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i> -Mutant Lung Adenocarcinoma. Cancer Discovery, 2018, 8, 822-835.	9.4	1,108
3	Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2018, 36, 2872-2878.	1.6	747
4	Cabozantinib in patients with advanced RET -rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. Lancet Oncology, The, 2016, 17, 1653-1660.	10.7	365
5	Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC. Cancer Immunology Research, 2018, 6, 1093-1099.	3.4	258
6	Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition. Cell, 2020, 183, 363-376.e13.	28.9	206
7	SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas. Journal of Thoracic Oncology, 2020, 15, 231-247.	1.1	172
8	Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status. Journal of Thoracic Oncology, 2022, 17, 399-410.	1.1	151
9	Response to ERBB3-Directed Targeted Therapy in <i>NRG1</i> -Rearranged Cancers. Cancer Discovery, 2018, 8, 686-695.	9.4	149
10	Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels. JAMA Oncology, 2022, 8, 1160.	7.1	117
11	Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas. Journal of Thoracic Oncology, 2015, 10, 1713-1719.	1.1	84
12	Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC. Clinical Cancer Research, 2020, 26, 2849-2858.	7.0	74
13	Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers. Journal of Thoracic Oncology, 2019, 14, 802-815.	1.1	71
14	Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study. European Journal of Cancer, 2019, 109, 28-35.	2.8	69
15	Dual-Energy CT Angiography for Detection of Pulmonary Emboli: Incremental Benefit of Iodine Maps. Radiology, 2018, 289, 546-553.	7.3	66
16	Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C–Mutant Non–Small Cell Lung Cancer. Clinical Cancer Research, 2021, 27, 2209-2215.	7.0	65
17	Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC. Journal of Thoracic Oncology, 2018, 13, 1530-1538.	1.1	62
18	Efficacy of Platinum/Pemetrexed Combination Chemotherapy in ALK-Positive NSCLC Refractory to Second-Generation ALK Inhibitors. Journal of Thoracic Oncology, 2020, 15, 258-265.	1.1	53

#	Article	IF	CITATIONS
19	Preoperative Computed Tomography Findings Predict Surgical Resectability of Thymoma. Journal of Thoracic Oncology, 2014, 9, 1023-1030.	1.1	42
20	Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non–Small Cell Lung Cancer. Clinical Cancer Research, 2021, 27, 5131-5140.	7.0	40
21	Deep Learning to Estimate RECIST in Patients with NSCLC Treated with PD-1 Blockade. Cancer Discovery, 2021, 11, 59-67.	9.4	38
22	Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status. , 2020, 8, e001007.		36
23	Postoperative complications after thoracic surgery for lung cancer. Clinical Imaging, 2015, 39, 735-749.	1.5	35
24	Safety of combining thoracic radiation therapy with concurrent versus sequential immune checkpoint inhibition. Advances in Radiation Oncology, 2018, 3, 391-398.	1.2	33
25	What CT characteristics of lepidic predominant pattern lung adenocarcinomas correlate with invasiveness on pathology?. Lung Cancer, 2018, 118, 83-89.	2.0	27
26	Pattern and Prognostic Implications of Cardiac Metastases Among Patients With Advanced Systemic Cancer Assessed With Cardiac Magnetic Resonance Imaging. Journal of the American Heart Association, 2016, 5, .	3.7	25
27	Prevalence of Occult Peribronchial N1 Nodal Metastasis in Peripheral Clinical N0 Small (â‰⊉ cm) Non-Small Cell Lung Cancer. Annals of Thoracic Surgery, 2020, 109, 270-276.	1.3	24
28	Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics. European Journal of Cancer, 2021, 151, 211-220.	2.8	24
29	From genotype to phenotype: Are there imaging characteristics associated with lung adenocarcinomas harboring RET and ROS1 rearrangements?. Lung Cancer, 2015, 90, 321-325.	2.0	23
30	Atypical presentation of Legionella pneumonia among patients with underlying cancer: A fifteen-year review. Journal of Infection, 2016, 72, 45-51.	3.3	16
31	Systemic and Oligo-Acquired Resistance to PD-(L)1 Blockade in Lung Cancer. Clinical Cancer Research, 2022, 28, 3797-3803.	7.0	15
32	Radiogenomic evaluation of lung cancer — Are there imaging characteristics associated with lung adenocarcinomas harboring BRAF mutations?. Clinical Imaging, 2017, 42, 147-151.	1.5	14
33	Computed tomography-derived assessments of regional muscle volume: Validating their use as predictors of whole body muscle volume in cancer patients. British Journal of Radiology, 2018, 91, 20180451.	2.2	12
34	Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic ROS1-Rearranged Lung Cancers. JTO Clinical and Research Reports, 2021, 2, 100187.	1.1	11
35	Case report of malignant pulmonary parenchymal glomus tumor: imaging features and review of the literature. Clinical Imaging, 2016, 40, 144-147.	1.5	9
36	CT features of HER2-mutant lung adenocarcinomas. Clinical Imaging, 2018, 51, 279-283.	1.5	9

#	Article	IF	CITATIONS
37	Perfusion defects on dual-energy CTA in patients with suspected pulmonary embolism correlate with right heart strain and lower survival. European Radiology, 2021, 31, 2013-2021.	4.5	9
38	Imaging of Thoracic Cavity Tumors. Surgical Oncology Clinics of North America, 2014, 23, 709-733.	1.5	8
39	A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung Cancers. Clinical Cancer Research, 2020, 26, 1796-1802.	7.0	8
40	Immune biomarkers and response to checkpoint inhibition of BRAFV600 and BRAF non-V600 altered lung cancers. British Journal of Cancer, 2022, 126, 889-898.	6.4	8
41	Percutaneous computed tomography guided biopsy of sub-solid pulmonary nodules: differentiating solid from ground glass components at the time of biopsy. Clinical Imaging, 2021, 69, 332-338.	1.5	7
42	Risk stratification of cardiac metastases using late gadolinium enhancement cardiovascular magnetic resonance: prognostic impact of hypo-enhancement evidenced tumor avascularity. Journal of Cardiovascular Magnetic Resonance, 2021, 23, 42.	3.3	7
43	Diagnostic utility and clinical implication of late gadolinium enhancement cardiac magnetic resonance for detection of catheter associated right atrial thrombus. Clinical Imaging, 2020, 62, 17-22.	1.5	4
44	Waxing and waning pattern of mTOR inhibitor-associated pneumonitis in renal cell carcinoma patients: A retrospective observational study. Clinical Imaging, 2021, 71, 29-33.	1.5	4
45	Are there imaging characteristics that can distinguish separate primary lung carcinomas from intrapulmonary metastases using next-generation sequencing as a gold standard?. Lung Cancer, 2021, 153, 158-164.	2.0	4
46	Immune checkpoint inhibitorâ€related pneumonitis: Acute lung injury with rapid progression and organizing pneumonia with less severe clinical disease. Histopathology, 0, , .	2.9	4
47	The effects of neoadjuvant chemotherapy and interval debulking surgery on body composition in patients with ovarian cancer. JCSM Clinical Reports, 2021, 6, 11-16.	1.3	3
48	Intra- and inter-reader agreement of iRECIST and RECIST 1.1 criteria for the assessment of tumor response in patients receiving checkpoint inhibitor immunotherapy for lung cancer. Lung Cancer, 2021, 161, 60-67.	2.0	2
49	Successful Use of Afatinib After Erlotinib-induced Pneumonitis in a Patient With Epidermal Growth Factor Receptor-mutant Lung Cancer. Clinical Lung Cancer, 2017, 18, e81-e83.	2.6	1
50	Type A thymoma presenting with bone metastasis. Histopathology, 2018, 73, 701-703.	2.9	1
51	Pre-treatment CT imaging in stage IIIA lung cancer: Can we predict local recurrence after definitive chemoradiotherapy?. Clinical Imaging, 2021, 69, 133-138.	1.5	1
52	COVID-19 in patients with cancer: can baseline radiologic severity and early evolution predict clinical outcomes?. European Radiology, 2021, , 1.	4.5	0
53	The effects of neoadjuvant chemotherapy and interval debulking surgery on body composition in patients with ovarian cancer. JCSM Clinical Reports, 2021, 6, 11-16.	1.3	Ο